News

BioGaia signs three new distribution agreements

27 Apr 2017

BioGaia has signed three new exclusive agreements for Prodentis, with Hansamed for sales in Canada, with BioCulture for sales in the Philippines and with MTC Pharma for sales in Vietnam.

BioGaia signs three new distribution agreements

BioGaia has signed three new exclusive agreements for Prodentis, with Hansamed for sales in Canada, with BioCulture for sales in the Philippines and with MTC Pharma for sales in Vietnam. All three distribution partners will sell Prodentis under the BioGaia brand and plan to launch during 2017.

BioGaia’s oral health products contain the patented and well-studied probiotic Lactobacillus reuteri Prodentis, which in close to 30 clinical studies has shown positive effects on gingivitis and periodontal disease.

The portfolio consists of lozenges and chewing gum for consumers and oil drops for professional use. Today BioGaia's oral health products are sold in more than 20 countries worldwide and the company says the strategy is to continue to expand this global network. As the market for probiotics in oral health is growing, BioGaia says it sees a large potential for Prodentis within the coming years.

Most of BioGaia’s partners selling Prodentis focus on medical marketing, and this will also be the business model in the three new countries.

”We have a very strong focus on developing our oral health business and our sales of Prodentis, for which we have strong clinical evidence. I am therefore very happy that we have signed another three agreements with solid partners in both Canada and Asia”, said Axel Sjöblad, Managing Director, BioGaia.